ArticleLung Cancer (Auckland, N.Z.)2026
Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study.
Article in Lung Cancer (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Targeted therapy improves survival of oncogene-driven NSCLC. We evaluate the clinical outcome of advanced NSCLC with oncogenic drivers in LC-SCRUM-Asia Taiwanese and Japanese cohort using tiered groups of disease-driven oncogene. Methods: Fourteen genes were reported from NGS and grouped into four tiers based on lines of approved targeted therapies in Taiwan and Japan (Tier 1: ≥ two lines; Tier 2: one line; Tier 3: not targetable; Tier 4: potentially targetable; not yet approved). Overall survival (OS) of the four-tier gene groups was analyzed in Taiwanese cohort and validated in the 8619 Japanese patients using a two-stage approach. Results: Three-hundred-fifty-nine patients were enrolled in Taiwanese cohort, of which 249 (69.4%) patients had a reported genomic alteration. Patients with a history of smoking (HR 0.46 [95% CI, 0.23-0.92]; p=0.031) and squamous cell carcinoma (HR 0.31 [95% CI, 0.12-0.78]; p=0.014) had a lower incidence of genomic alterations. The top five genomic alterations were Conclusion: The available lines of targeted therapy impact survival in patients of advanced oncogene-driven NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.